Session Time: 12:30pm-2:00pm
Location: Exhibit Hall located in Hall B, Level 2
Objective: To analyze the association between aminosalicylate-treated inflammatory bowel disease (IBD-A) and Parkinson´s disease (PD) at population level.
Background: According to the dual-hit hypothesis, the neuropathological process that leads to PD starts in the enteric nervous system or olfactory bulb. Intestinal inflammation and/or changes in bacterial flora may modify the risk of alpha-synuclein aggregation and/or propagation. There is an apparently low association between PD and IBD, despite the major prevalence of the two diseases.
Methods: A cross-sectional study was conducted based on the electronic prescribing system of the Andalusian public health system (covers 98% of prescriptions), including all patients aged ≥ 50 yrs who received medication during December 2014. Cases were identified as “possible PD” when they received antiparkinson drugs (excluding those who only had one low-dose dopaminergic agonist), and as "possible IBD” when they received aminosalicylates (mesalazine, sulfasalazine, or 5-ASA).
Results: During the study period, 2,020,868 patients were recorded (68 ± 11 yrs, 56% female): 19,966 of these were identified as “possible PD” (75±9 yrs, 53% female) and 7,485 as “possible IBD” (64±10 yrs, 47% female). Only 56 patients were included in both groups (76±8 yrs; 32 males); the prevalence of PD was 0.7% in patients with IBD and 1% in those without (OR=0.75; 95% CI=0.57-0.98; p=0.036). The age- and sex-adjusted OR was 0.28 (95% CI=0.10-0.74; p=0.01) in patients aged ≤65 yrs and 1.17 (95% CI=0.89-1.54; p=0.257) in those aged >65 yrs.
Conclusions: Within the limitations of the methodology applied, these findings suggest a protective role for IBD and/or aminosalicylates against PD development, especially in under-65-yr olds. Further longitudinal studies are required on this association, given the important scientific and therapeutic implications.
To cite this abstract in AMA style:F. Escamilla-Sevilla, J. Pinel-Ríos, C.J. Madrid-Navarro, R. Piñar-Morales, J.D. Herrera-García, M.J. Pérez-Navarro, C. Del Canto-Pérez, M.J. Cabello-Tapia, M.d.m. Martín-Rodríguez, D. Sánchez-Capilla, M.J. Piña-Vera, A. Aguilar-Muñoz, V. Campos-Arillo, J. Gutiérrez-García, C.E. Chamorro-Santos, M.R. Gómez-García, A. Mínguez-Castellanos. Are inflammatory bowel disease and/or treatment with aminosalicylates protective factors against Parkinson’s disease? [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/are-inflammatory-bowel-disease-andor-treatment-with-aminosalicylates-protective-factors-against-parkinsons-disease/. Accessed December 5, 2023.
« Back to 2016 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/are-inflammatory-bowel-disease-andor-treatment-with-aminosalicylates-protective-factors-against-parkinsons-disease/